Logo-jrip
ePublished: 29 Jul 2016
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2016;5(3): 162-167.
doi: 10.15171/jrip.2016.34
PMID: 27689115
PMCID: PMC5040005
  Abstract View: 4791
  PDF Download: 2179

Original Article

The effect of lactulose supplementation on fecal microflora of patients with chronic kidney disease; a randomized clinical trial
 

Hamid Tayebi-Khosroshahi 1, Afshin Habibzadeh 2, Bahram Niknafs 1, Reza Ghotaslou 1, Fatemeh Yeganeh Sefidan 1, Morteza Ghojazadeh 1, Majid Moghaddaszadeh 1, Sahar Parkhide 1

1 Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Medical Education Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
*Corresponding Author:

Abstract

Introduction: Lactulose is a prebiotic with bifidogenic and urea reduction effects. It can improve Bifidobacteria and Lactobacilli counts in healthy humans and it may possibly have similar effects in chronic kidney disease (CKD) patients.

Objectives: To investigate the effect of lactulose on fecal microflora of patients with CKD.

Patients and Methods: Thirty-two patients with stages 3 and 4 of CKD (43.8% male with mean age of 58.09±12.75 years) were randomly assigned to intervention (n=16) and control (n=16) groups. Patients in intervention group received 30 mm lactulose syrup three times a day for an 8-week period. Control group received placebo 30 mm three times a day. A fecal sample was obtained from all patients at the beginning and at the end of the study and Bifidobacteria and Lactobacilli was counted.

Results: Creatinine (Cr) significantly decreased in intervention group (3.90±1.43 to 3.60±1.44, P=0.003) and increased in control group (3.87±2.08 to 4.11±1.99, P=0.03). Although Bifidobacterial and Lactobacilli counts were similar before intervention, they were significantly higher at the end of the study in lactulose group (P=0.01 and P=0.04, respectively). Lactulose led to significant increase in fecal Bifidobacterial counts (3.61±0.54 to 4.90±0.96, P<0.001) and Lactobacilli counts (2.79±1.00 to 3.87±1.13, P<0.001), while the change in placebo group was not significant.

Conclusion: Lactulose administration will increase Bifidobacteria and Lactobacillus counts in patients with CKD.

 

Implication for health policy/practice/research/medical education:

Lactulose as a prebiotic can improve Bifidobacteria and Lactobacilli counts. The aim is the evaluation of lactulose on intestinal flora of chronic kidney disease patients. We used lactulose and compared the bifidobacteria and lactobacillus colony counts and also nitrogenous waste products with control patients. There was significant reduction of urea, creatinine in improvement of Bifidobacteria and Lactobacillus counts.

Please cite this paper as: Tayebi-Khosroshahi H, Habibzadeh A, Niknafs B, Ghotaslou R, Yeganeh Sefidan F, Ghojazadeh M, et al. The effect of lactulose supplementation on fecal microflora of patients with chronic kidney disease; a randomized clinical trial. 2016;5(3):162-167. DOI: 10.15171/jrip.2016.34

 
 
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 4792

Your browser does not support the canvas element.


PDF Download: 2179

Your browser does not support the canvas element.